Table 1.
Demographics and disease characteristics by continuation of EGFR TKI at RECIST PD.
| Characteristics | Continued TKI (n = 49) | Discontinued TKI (n = 7) | Total (n = 56) |
|---|---|---|---|
| Sex | |||
| Female | 41 (84) | 5 (71) | 46 (82) |
| Male | 8 (16) | 2 (29) | 10 (18) |
| Age | |||
| Mean (SD) | 63.0 (11.1) | 48.0 (9.0) | 61.1 (11.9) |
| Median (Q1,Q3) | 64 (54,73) | 48 (44,50) | 63 (51,71) |
| [Range] | [38–79] | [35–65] | [35–79] |
| Race | |||
| White | 44 (90) | 7 (100) | 51 (91) |
| Asian | 3 (6) | 0 (0) | 3 (5) |
| Black | 2 (4) | 0 (0) | 2 (4) |
| Smoking status | |||
| Never | 24 (49) | 4 (57) | 28 (50) |
| Former | 24 (49) | 3 (43) | 27 (48) |
| Current | 1 (2) | 0 (0) | 1 (2) |
| Histology | |||
| Adenocarcinoma | 47 (96) | 5 (71) | 52 (93) |
| NSCLC NOSa | 2 (4) | 2 (29) | 4 (7) |
| ECOG Performance statusb | |||
| 0 | 21 (43) | 3 (43) | 24 (43) |
| 1 | 27 (55) | 3 (43) | 30 (54) |
| 2 | 1 (2) | 1 (14) | 2 (4) |
| Distant metastasis | 26 (53) | 6 (86) | 32 (57) |
| TKI | |||
| Erlotinib | 45 (92) | 5 (71) | 50 (89) |
| Gefitinib | 4 (8) | 2 (29) | 6 (11) |
| EGFR mutation | |||
| Exon 19 del | 28 (57) | 4 (57) | 32 (57) |
| Exon 19 del and L861Q | 1 (2) | 0 (0) | 1 (2) |
| L858R | 15 (31) | 3 (43) | 18 (32) |
| L861Q | 1 (2) | 0 (0) | 1 (2) |
| L861Q and G719 | 1 (2) | 0 (0) | 1 (2) |
| G719 | 3 (6) | 0 (0) | 3 (5) |
| T790Mc | 1 (2) | 1 (14) | 2 (4) |
| Other EGFR mutation | 9 (18) | 0 (0) | 9 (16) |
The values in parenthesis represent the percentage unless otherwise specified.
a
NSCLC NOS, Non-small-cell lung cancer not otherwise specified.
b
ECOG, Eastern Cooperative Oncology Group.
c
The patients had been exposed to EGFR-TKI before tissue sampling, which demonstrated both T790M mutation and a sensitizing mutation of EGFR.